Adial Pharmaceuticals, Inc. Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage
Adial Pharmaceuticals, Inc. (ADIL) had Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage of 100.00% as of 2021-01-26, per its 10-Q filed 2021-05-17.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage · last filed 2021-05-17
- 2021-01-26: Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage 100.00%.
| Period end | Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage |
|---|---|
| 2021-01-26 | 100.00% 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |